GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Investor Presentation

Mgmt Guided Margin ImprovementInvestor Communications View source PDF

GLAXO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.2%1-day move

₹2410.00

prior close

₹2437.10

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.5+0.7+0.2-0.9+1.2-0.8-0.9-2.6-4.0-4.6-10.2-12.2+2.3—

Up moveDown movePending

AI summary

GSK India reported FY26 standalone revenue of ₹3790 crore, up 2% YoY, with first-ever PAT crossing ₹1000 crore at ₹1010 crore (margin 26.8%, +200bps). EBITDA stood at ₹1300 crore with 34.3% margin, expanding 290bps YoY. Q4 FY26 revenue was ₹989 crore (+2%) with PAT of ₹275 crore (+6%). The company highlighted portfolio shift toward innovative therapies contributing 6% of sales, with strong growth in Shingrix (56% YoY) and new oncology launches. GSK rep market grew 7.3% vs IPM growth of 8.9%. The company has 26 ongoing clinical trials and maintains strong cash position of ₹2746 crore. Final dividend of ₹57 per share declared.

Likely market impact

Strong margin expansion and first-ever PAT milestone indicate improving operational efficiency and cost management. Portfolio transformation toward specialty and innovative drugs positions the company for sustainable growth, though supply constraints remain a near-term headwind.